Patrick G Pilie

Patrick G Pilie

UNVERIFIED PROFILE

Are you Patrick G Pilie?   Register this Author

Register author
Patrick G Pilie

Patrick G Pilie

Publications by authors named "Patrick G Pilie"

Are you Patrick G Pilie?   Register this Author

17Publications

494Reads

32Profile Views

PARP Inhibitors: Extending Benefit Beyond -Mutant Cancers.

Clin Cancer Res 2019 Jul 13;25(13):3759-3771. Epub 2019 Feb 13.

Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/lookup/doi/10.1158/107
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-18-0968DOI Listing
July 2019

Durable complete response in renal cell carcinoma clinical trials.

Lancet 2019 06 9;393(10189):2362-2364. Epub 2019 May 9.

Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(19)30949-3DOI Listing
June 2019

State-of-the-art strategies for targeting the DNA damage response in cancer.

Nat Rev Clin Oncol 2019 02;16(2):81-104

Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41571-018-0114-z
Publisher Site
http://dx.doi.org/10.1038/s41571-018-0114-zDOI Listing
February 2019

SET-ing the stage for PI3Kβ inhibitor sensitivity in clear cell renal cell carcinoma.

Oncotarget 2019 Feb 22;10(16):1540-1541. Epub 2019 Feb 22.

Department of Genitourinary Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.26709DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6422188PMC
February 2019

Development of PARP and Immune-Checkpoint Inhibitor Combinations.

Cancer Res 2018 12 29;78(24):6717-6725. Epub 2018 Nov 29.

Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine; Khalifa Institute for Personalized Cancer Therapy; Department of Thoracic/Head and Neck Medical Oncology; The Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://cancerres.aacrjournals.org/lookup/doi/10.1158/0008-54
Publisher Site
http://dx.doi.org/10.1158/0008-5472.CAN-18-2652DOI Listing
December 2018

Broadening the View of Germline Mutations in Kidney Cancer.

JAMA Oncol 2018 09;4(9):1235-1236

Department of Internal Medicine and Huntsman Cancer Institute, University of Utah, Salt Lake City.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2018.2015DOI Listing
September 2018

Precision Medicine: Progress, Pitfalls, and Promises.

Mol Cancer Ther 2017 12;16(12):2641-2644

The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-17-0904DOI Listing
December 2017

Germline genetic variants in men with prostate cancer and one or more additional cancers.

Cancer 2017 Oct 28;123(20):3925-3932. Epub 2017 Jun 28.

Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.30817DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6108085PMC
October 2017

Systematic Review: Perioperative Systemic Therapy for Metastatic Renal Cell Carcinoma.

Kidney Cancer 2017 Jul 26;1(1):57-64. Epub 2017 Jul 26.

University of Texas, MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://www.medra.org/servlet/aliasResolver?alias=iospress&am
Publisher Site
http://dx.doi.org/10.3233/KCA-170009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6179116PMC
July 2017

HOXB13 and other high penetrant genes for prostate cancer.

Asian J Androl 2016 Jul-Aug;18(4):530-2

Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan Medical School and The University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA.

View Article

Download full-text PDF

Source
http://www.ajandrology.com/text.asp?2016/18/4/530/175785
Publisher Site
http://dx.doi.org/10.4103/1008-682X.175785DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4955175PMC
March 2017

Key considerations in the treatment of von Hippel-Lindau disease.

Future Oncol 2016 Aug 29;12(15):1755-8. Epub 2016 Mar 29.

Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2016-0028DOI Listing
August 2016